Catalyst PharmaceuticalCPRX
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Employees: 167
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
98% more call options, than puts
Call options by funds: $490K | Put options by funds: $248K
71% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 35
53% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 91
8% more capital invested
Capital invested by funds: $1.9B [Q3] → $2.06B (+$156M) [Q4]
7% more funds holding
Funds holding: 312 [Q3] → 333 (+21) [Q4]
1.27% more ownership
Funds ownership: 80.62% [Q3] → 81.89% (+1.27%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Baird Joel Beatty 38% 1-year accuracy 15 / 40 met price target | 42%upside $32 | Outperform Maintained | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 35% 1-year accuracy 123 / 356 met price target | 55%upside $35 | Buy Reiterated | 28 Feb 2025 |
Stephens & Co. Sudan Loganathan 23% 1-year accuracy 6 / 26 met price target | 46%upside $33 | Overweight Reiterated | 27 Feb 2025 |
B of A Securities Jason Gerberry 43% 1-year accuracy 9 / 21 met price target | 33%upside $30 | Buy Reiterated | 9 Jan 2025 |
Financial journalist opinion
Based on 10 articles about CPRX published over the past 30 days









